KLRC2 and myeloid sarcoma: These findings raise the question of whether the induction of high-level NKG2C+ NK cells, potentially via therapeutic vaccination with highly potent UL40 peptides or through cellular immunotherapies, could serve as an additional option to limit the pathogenesis and progression of MS.